AU InforMed

Key Inforbits

- New drug for colorectal cancer
- Another maker of flu vaccine
- Patient counseling breakdowns
- New isn’t necessarily better!
- Phenylephrine dissatisfaction coming?
- Report those “statin” side effects

NEW DRUGS, and other related stuff …

New Drug … The FDA approved panitumumab (Vectibix™ by Amgen Inc) on September 27, 2006 for the treatment of patients with colorectal cancer that has metastasized following standard chemotherapy. It is a monoclonal antibody that binds to a protein called epidermal growth factor receptor or EGFR on some cancer cells. Panitumumab received an accelerated approval after showing effectiveness in slowing tumor growth and, in some cases, reducing the size of the tumor. In the U.S. it is estimated that 150,000 new cases of colon cancer will be diagnosed and 55,000 deaths will occur from colon and rectal cancer in 2006. Approximately 70% of all colorectal carcinomas are EGFR positive. As part of the approval, Amgen committed to conduct a postmarketing trial to show whether the drug improves patients’ survival in patients with fewer prior chemotherapies. In addition, the drug is priced at $4000 per dose for roughly a few additional months of life.

http://www.fda.gov/bbs/topics/NEWS/2006/NEW01468.html


New Flu Vaccine … The FDA approved FluLaval® (manufactured by ID Biomedical Corporation of Quebec, Canada, a subsidiary of GlaxoSmithKline Biologics, distributed by GlaxoSmithKline), October 5, 2006, to immunize people 18 years of age and older against the disease caused by strains of influenza virus judged likely to cause seasonal flu in the Northern Hemisphere in 2006-2007. There are now five FDA-licensed vaccines for the U.S. for the upcoming influenza season. According to the Centers for Disease Control and Prevention (CDC), the manufacturers have projected making a total of about 115 million doses of influenza vaccine for the 2006–2007 season, but these projections could change as manufacturing continues. According to CDC, every year in the U.S., on average: 5% to 20% of the population gets seasonal flu; more than 200,000 people are hospitalized; and about 36,000 people die.

FDA approves additional vaccine for upcoming influenza season. FDA News. 2006 Oct 5; P06-156.
http://www.fda.gov/bbs/topics/NEWS/2006/NEW01478.html

New Dose Form … The FDA approved fentanyl buccal tablets (Fentora™ by Cephalon) on September 25, 2006, for the management of breakthrough pain in patients with cancer who are already receiving, and who are tolerant to opioid therapy for their underlying persistent cancer
pain. Its proprietary OraVescent® drug delivery system was developed by Cephalon subsidiary CIMA LABS; Fentora™ is covered by patents until 2019. It is a Schedule II product. [Manufacturer web site; press release; prescribing information]

**MedWatch** ... Genentech and FDA announced revisions to the WARNINGS and ADVERSE REACTIONS sections of the prescribing information concerning 1] cases of a rare brain-capillary leak syndrome [reversible posterior leukoencephalopathy syndrome (RPLS)] and 2] postmarketing reports of nasal septum perforation. RPLS is a neurological disorder associated with hypertension, fluid retention and cytotoxic effects of immunosuppressive drugs on the vascular endothelium. The syndrome can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances. Mild to severe hypertension may be present, but is not necessary for diagnosis. The onset of symptoms has been reported to occur from 16 hours to 1 year after initiation of Avastin. Magnetic Resonance Imaging (MRI) is necessary to confirm the diagnosis of RPLS.

Read the complete MedWatch 2006 Safety summary, including links to the Sponsor's Dear Healthcare Provider Letter and updated prescribing information regarding this issue at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#Avastin

**MedWatch** ... The FDA announced preliminary information from the North American Antiepileptic Drug Pregnancy Registry that suggests that babies exposed to lamotrigine (Lamictal® by GlaxoSmithKline), indicated to treat seizures and bipolar disorder, during the first three months of pregnancy may have a higher chance of being born with a cleft lip or cleft palate. Women who are pregnant and taking Lamictal® or who are thinking about taking it are urged not to start or stop taking the medication without first talking to their physician.

Read the complete MedWatch 2006 Safety summary, including links to the FDA Patient Information Sheet and Healthcare Professional Information, regarding this issue at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#Lamictal

**MedWatch** ... FDA and Bristol-Myers Squibb notified pharmacists and physicians of revisions to the labeling for Coumadin® (warfarin), to include a new patient Medication Guide as well as a reorganization and highlighting of the current safety information to better inform providers and patients. The FDA regulation 21CFR 208 requires a Medication Guide to be provided with each prescription that is dispensed for products that FDA determines pose a serious and significant public health concern.

Information about all currently approved Medication Guides is available at: http://www.fda.gov/cder/Offices/ODS/medication_guides.htm

Read the complete MedWatch 2006 Safety summary, including links to the new Medication Guide, revised prescribing information and supplemental supporting documents, at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#Coumadin

**MedWatch** ... FDA and the iPLEDGE program announced an update to iPLEDGE, a risk management program to reduce the risk of fetal exposure to isotretinoin, that will eliminate one element of the program, the 23 day lock-out period for males and females of non-child bearing potential. This change does not affect female patients of child-bearing potential.

Read the complete MedWatch Safety summary, including links to the Dear Healthcare professional letter and supplemental FDA information, at: http://internet-dev/medwatch/safety/2006/safety06.htm#Isotretinoin

*AU InforMed*, vol. 4, no. 30, Monday, October 9, 2006 118
**Physician, listen to thyself** … From a variety of physician practices in California an observational study, using surveys and transcribed audiotapes of office visits, measured the quality of physician communication when prescribing new medication. On a scale of 5, the average score was 3.1. They did best on the easy stuff (eg, name, purpose) and worst on adverse effects and administration information. Clearly this is a problem for patients. Pharmacy should be easily covering this gap, but are we??


**Old drugs better than new ones??** … In a study of 227 patients in England that required a change in therapy for schizophrenia, quality of life scores, symptoms, adverse effects, participant satisfaction and costs of care were recorded. Blind assessments were made at 12, 26 and 52 weeks of therapy. Therapies were the second generation (atypical) antipsychotics and the first generation (typical) antipsychotics (clozapine was excluded). Results showed that quality of life scales and symptom scores improved with the first generation antipsychotics, costs were similar and patients had no overall preference. Another important point for this study, it was not funded by any commercial enterprise.


Two commentaries were also published in the same issue, both from the U.S. Both were interesting in that they were lamenting both the state of antipsychotic therapy (ie, if the second generations aren’t any better, then we haven’t progressed very far over a half century).

Lieberman JA. Comparative effectiveness of antipsychotic drugs. *Arch Gen Psychiatry.* 2006 Oct;63:1069-72.


**Children vulnerable to flu** … In a recent report by state, the CDC indicated that in the 2004-2005 influenza season, the percentage of children fully vaccinated ranged from 3.3% to 35.5%. This was the first year for a full recommendation for vaccination for the age group of 6-23 months and approximately double of the previous year. The point is also made that protection of children is also enhanced when household contacts and caregivers are also vaccinated.


[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5539a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5539a1.htm)

**Reviews of Note** …


Phenylephrine dissatisfaction … A recent article reporting on apparent patient dissatisfaction with the pseudoephedrine replacement drug, phenylephrine. Due to recent federal (and state) legislation, pseudoephedrine is now more difficult to purchase, amounts and times are limited, all in an effort to reduce availability of a methamphetamine precursor. Phenylephrine has become the decongestant of choice to replace it. The problem is, it may not be as effective, at least in the recommended dose, and has a shorter duration. The data is based on an FDA review in 1976; new studies are underway, but prepare for patient complaints about phenylephrine products.


Statin side effects … The “statins” have been around awhile now, but the medical community is still concerned about their adverse effects. The point is made that even though numerous studies show their benefit, studies specifically designed to determine risk are underrepresented. One group from the University of California-San Diego feels that patient complaints may not meet with the proper concern from practitioners, so they have set up a web site specifically for patients to report side effects of “cholesterol” drugs. Their primary aim is to try to determine the real incidence of adverse effects of these drugs. The web site is [www.statineffects.com](http://www.statineffects.com)


AUBURN HSOP FACULTY in the literature …


NEW RESOURCES in the DILRC …


The last “dose” …

“As the pie gets smaller, the table manners get worse.”

William Zellmer, quoting Henri Manasse (both of ASHP).

Actual author unknown.

*AU InforMed*, vol. 4, no. 30, Monday, October 9, 2006